Predicting the public health impact of bivalent vaccines and nirmatrelvir-ritonavir against COVID-19.

Hailey J ParkSophia T TanTomás M LeónSeema JainRobert SchechterNathan C Lo

Published in: medRxiv : the preprint server for health sciences (2023)

These findings suggest prioritizing uptake of bivalent boosters and nirmatrelvir-ritonavir among the oldest age groups would be efficient and have substantial public health impact in reducing the burden of severe COVID-19, but would not address the entire burden of severe COVID-19.

Keyphrases

public health
coronavirus disease
sars cov
early onset
respiratory syndrome coronavirus
antiretroviral therapy
risk factors
drug induced